Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oman Healthcare News.
Press releases published on September 17, 2025
Oruka Therapeutics Announces $180 Million Private Placement
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, …
Navigator Medicines Announces Positive Phase 1a Data from its Program of Potential Best-in-Class Bispecific Antibodies; NAV-240 Poised for Further Development in Inflammatory Disorders and Autoimmune Diseases
Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development Phase 1b study fully enrolled and data expected in early 2026 Further clinical development of NAV-240 to begin in early 2026 SCOTCH PLAINS, N.J., Sept. 17, …
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary endpoints in biologic-naïve patients compared to placebo …
Communiqué de presse : EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée
EADV : Les résultats de l’étude de phase 2a montrent que le brivekimig de Sanofi est efficace dans le traitement de l’hidrosadénite suppurée Dans l’étude de phase 2a, le brivekimig a entraîné des améliorations cliniquement significatives des critères d’ …
Oruka Therapeutics Announces Positive Interim Phase 1 Results for ORKA-001
Half-life of approximately 100 days increases likelihood of once-per-year dosing Pharmacokinetic profile supports the ability to achieve exposures that could lead to higher efficacy and extended off-treatment remissions Well tolerated with a favorable …
Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes
SOUTH SAN FRANCISCO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (“Cytokinetics”) (Nasdaq: CYTK) today announced the pricing of its offering of $650.0 million aggregate principal amount of 1.75% convertible senior notes due 2031 …